Clever Leaves and the biopharmaceutical research company at

0


The initiative is part of the Change Lives project; Clever Leaves’ $ 25 Million Proceeds Commitment to Help Cannabis Research in the United States Collaboration represents the first company-funded study with a research institute in the United States

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) – Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical grade cannabinoids , and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for the import, analysis and manufacture of controlled substances in the United States, today announced a joint partnership with the goal of to study the variation of the cannabis DNA sequence of three Clever Leaves. cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), with accepted research sponsorship from BRC, will lead DNA extraction and analysis to elucidate genetic variants from various genetic lines of Cannabis sativa.

Project Change Lives is a United States-based initiative sponsored by Clever Leaves, in which the company has pledged to contribute up to $ 25,000,000 in retail value of medical cannabis products to any organization. US eligible to advance scientific research into the potential medical benefits of cannabinoids. By sponsoring the Change Lives project, Clever Leaves aims to supply a historic amount of pharmaceutical grade cannabis to leading research institutes in one of the most advanced pharmaceutical markets in the world.

UC Davis will be the first major research institution to collaborate on Clever Leaves’ Colombian and Portuguese pharmaceutical grade cannabis investigation as part of the Change Lives project.

Clever Leaves will provide three of its cultivars to BRC for testing at their facilities. UC Davis researchers will extract DNA for sequencing and analysis of cannabis samples at BRC facilities. Scientists at UC Davis will also test new approaches to extract RNA from dried material. If successful, researchers will analyze the data to quantify overall gene expression and use available pipelines to determine differential gene expression between the three lines sampled. These data will provide fundamental information to initiate new crosses and a breeding pipeline for the future to ensure the genetic variation of Cannabis sativa can be used to provide new and unique medicinal cannabis for new pharmaceutical products.

In addition, analysis of the completed data will reveal the correlation between specific cannabis genotypes and the biochemical phenotypes of cannabinoids and terpenes. Upon completion of the study, UC Davis intends to provide a report that provides insight into the genetic diversity of the lines and the feasibility of RNA extraction and gene expression from Cannabis sativa Equipment. These results will be widely disseminated for the benefit of the medical and scientific community – a result that meets one of the key objectives of the Change Lives project.

“We are honored to collaborate with the Plant Science department at UC Davis,” said Kyle Detwiler, CEO of Clever Leaves. “UC Davis consistently ranks among the world’s top plant science programs and shares our commitment to apply greater scientific rigor to cannabis research to better understand the potentially life-saving applications of cannabinoid medicine. We are truly delighted that UC Davis has become the first US research institution to align with Project Change Lives, and we look forward to the initiative’s expansion.

Distinguished Professor Gail Taylor, Principal Investigator of the Research Project and John B. Orr Chair of the Plant Sciences Department at UC Davis added: “This new project will provide insight into the apparent genetic variation in the contrasting lineages of Cannabis sativa and is part of a larger program at UC Davis to unravel this variation and begin breeding cultivars to aid the medicinal cannabis industry.

“What a privilege it is to partner with Clever Leaves and UC Davis for such a worthy cause in Project Change Lives,” said George Hodgin, CEO of Biopharmaceutical Research Company. “The reputation of UC Davis’ plant science program, coupled with the generosity and leadership of Clever Leaves, is sure to lead to powerful breakthroughs. We are thrilled to be a part of it and look forward to working with them to expand research on groundbreaking cannabis processing discoveries through this program. “

As part of the Change Lives project, Clever Leaves has committed to supply up to 250,000 bottles of pharmaceutical grade cannabis oils or approximately 5 tonnes of medicinal cannabis flowers that will help research institutes develop new therapies. . To remove an additional barrier to the advancement of scientific knowledge about cannabis, this research material will be provided free of charge to Clever Leaves research partners. Organizations interested in applying can visit www.projectchangelives.org for more information.

About Clever Leaves Holdings Inc.
Clever Leaves is a multinational cannabis company focused on large-scale, ecologically sustainable cultivation and processing of pharmaceutical grade cannabinoids as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an efficient distribution network and global presence, with a foundation built on capital efficiency and growth. fast. Clever Leaves aims to be one of the industry’s leading global cannabis companies, recognized for its principles, people and performance, while fostering a healthier global community. Clever Leaves has received several international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including the European Union Good Manufacturing Practices (EU GMP) certification, a certification of Good Manufacturing Practices (GMP) by Colombia’s National Food and Drug Surveillance. Institute – Invima Certification and Good Agricultural and Collecting Practices (GACP). Clever Leaves has obtained a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to grow, import and export dry flowers for medicinal and research purposes. In addition, the Portuguese operation has also obtained certification of compliance with GACP and IMC-GAP standards.

For more information, please visit https://cleverleaves.com/en/home/ and follow us on LinkedIn.

About the biopharmaceutical research company
Biopharmaceutical Research Company (“BRC”) is a specialty pharmaceutical company that holds multiple DEA registrations and helps pave the way for the legal cannabis space at the federal level in the United States. BRC also conducts cannabis-specific testing activities that comply with federal law.

Clever Leaves press contacts:
Rich DiGregorio
KCSA strategic communication
+ 1-347-487-6182
[email protected]

Diana Sigüenza
Director of Strategic Communication
+ 57-310-236-8830
[email protected]

Clever leaves investor demands:
Cody slach
Investor Relations Gateway
+ 1-949-574-3860
[email protected]

Clever Leaves business inquiries:
Andrew Miller
Vice President of Sales – EMEA, North America and Asia-Pacific
+ 1-416-817-1336
[email protected]

Change Lives Project Inquiries:
[email protected]


Share.

Comments are closed.